Business Context and Reporting Period
This Form 8-K Current Report from Accendra Health, Inc. (ACH) covers events occurring on May 14, 2026, specifically the 2026 Annual Meeting of Shareholders. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, executive compensation, and equity incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results rather than financial performance data.
Material Changes and Voting Results
At the Annual Meeting, 62,134,133 shares were voted, representing approximately 81.29% of the 76,437,917 shares entitled to vote. Key outcomes include:
- Director Elections: Six directors were elected for one-year terms. While all were approved, Edward A. Pesicka received the highest number of "Against" votes (3,497,266) compared to his peers.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: The non-binding advisory vote to approve named executive officer compensation passed, though it received 4,098,288 "Against" votes.
- Equity Plan Approval: Shareholders approved the Amended and Restated 2023 Omnibus Incentive Plan, which authorizes the Board to grant equity and incentive awards to employees, directors, and consultants.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary focus is the administrative approval of the Amended and Restated 2023 Plan, which replaces the Owens & Minor, Inc. 2023 Omnibus Incentive Plan.
Investor Verification Checklist
- Verify the specific terms of the Amended and Restated 2023 Omnibus Incentive Plan in the proxy statement filed on April 2, 2026, to understand potential dilution or compensation structures.
- Review the voting dissent for Director Edward A. Pesicka and the executive compensation vote to gauge shareholder sentiment.
- Confirm the broker non-votes (9,763,670 shares) which were excluded from the vote totals for directors, compensation, and the equity plan.
- Check subsequent filings for the 2026 Annual Report (10-K) to obtain the financial metrics absent from this 8-K.